Recent Advances in Targeted Therapy for Glioma

Author(s): Lin Lin, Jinquan Cai*, Chuanlu Jiang*.

Journal Name: Current Medicinal Chemistry

Volume 24 , Issue 13 , 2017

  Journal Home
Translate in Chinese

Abstract:

Gliomas are the most common primary malignant brain tumors, which have a universally fatal outcome. Current standard treatment for glioma patients is surgical removal followed by radiotherapy and adjuvant chemotherapy. Due to therapeutic resistance and tumor recurrence, efforts are ongoing to identify the molecules that are fundamental to regulate the tumor progression and provide additional methods for individual treatment of glioma patients.

By studying the initiation and maintenance of glioma, studies focused on the targets of tyrosine kinase receptors including EGFR, PDGFR and other crucial signal pathways such as PI3K/AKT and RAS/RAF/MAPK pathway. Furthermore, recent advances in targeting immunotherapy and stem cell therapy also brought numerous strategies to glioma treatment. This article reviewed the researches focused on the advanced strategies of various target therapies for improving the glioma treatment efficacy, and discussed the challenges and future directions for glioma therapy.

Keywords: Glioma, clinical trials, targeted therapy, cell signal transduction pathway, glioma stem cell, Immunotherapy.

Rights & PermissionsPrintExport Cite as

Article Details

VOLUME: 24
ISSUE: 13
Year: 2017
Page: [1365 - 1381]
Pages: 17
DOI: 10.2174/0929867323666161223150242
Price: $58

Article Metrics

PDF: 44
HTML: 4
EPUB: 3
PRC: 3